1. Home
  2. DNOW vs MLYS Comparison

DNOW vs MLYS Comparison

Compare DNOW & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOW Inc.

DNOW

NOW Inc.

N/A

Current Price

$11.26

Market Cap

2.7B

Sector

Industrials

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$27.26

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DNOW
MLYS
Founded
1862
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
DNOW
MLYS
Price
$11.26
$27.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$16.67
$47.33
AVG Volume (30 Days)
3.6M
988.0K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,648,000,000.00
N/A
Revenue This Year
$70.53
N/A
Revenue Next Year
$8.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.68
N/A
52 Week Low
$11.10
$10.44
52 Week High
$17.48
$47.65

Technical Indicators

Market Signals
Indicator
DNOW
MLYS
Relative Strength Index (RSI) 30.85 41.11
Support Level N/A $26.85
Resistance Level $15.93 $30.05
Average True Range (ATR) 0.56 1.76
MACD -0.11 0.08
Stochastic Oscillator 8.46 29.78

Price Performance

Historical Comparison
DNOW
MLYS

About DNOW NOW Inc.

Dnow Inc is a company engaged in world-wide supplying of energy and industrial products and packaged, engineered process and production equipment with a legacy of over one sixty years. It offers a broad set of supply chain solutions combined with a suite of digital solutions branded as DigitalNOW that provide customers world-class technology for digital commerce, data and information management. Its locations provide products and solutions to exploration and production companies, midstream transmission and storage companies, refineries, chemical companies, utilities, mining, municipal water, manufacturers, engineering and construction companies. The Company has three reportable segments being United States, Canada and International.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: